

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**COMP/M.6851- BAXTER INTERNATIONAL / GAMBRO**

**SECTION 1.2**

**Description of the concentration**

1. Baxter International Inc. has entered into an agreement to acquire Gambro AB. Since Baxter will acquire sole control of Gambro, the Transaction constitutes a concentration within the meaning of Article 3(1)(b) of the EUMR.
2. Baxter is a diversified healthcare company, which develops, manufactures and markets products used in the treatment of patients suffering from hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
3. Gambro is a medical technology company, which develops, manufactures and supplies products and therapies for acute and chronic kidney dialysis, liver dialysis, myeloma kidney therapy, related water systems and other extracorporeal therapies for chronic and acute patients.
4. The Transaction concerns renal replacement therapy products.
5. The Transaction will improve Baxter's ability to provide dialysis products to customers globally, enable Baxter to save costs by gaining scale, enhance Baxter's ability to expand its product offering, and accelerate and broaden innovation, thus improving therapies and the quality of patients' lives.